BioStem Technologies (BSEM) Surges Ahead with Record Revenues, Insider Buying, and Breakthrough Clinical Pipeline—Could This Be the Next Big Winner in MedTech?

BioStem Technologies Inc. (OTC: BSEM) is redefining the future of regenerative medicine and wound care—and investors are taking notice.

The company develops groundbreaking therapies to accelerate healing in chronic and complex wounds—such as diabetic foot ulcers and venous leg ulcers. Its flagship VendajeAC line, along with an expanding portfolio of advanced regenerative products, is rapidly gaining adoption across hospitals, clinics, and specialty care centers, driving a significant surge in revenue.

In Q2 2025, BioStem posted preliminary results, generating $49.3 million in net revenue and achieving its sixth consecutive quarter of positive adjusted EBITDA of $2.5 million. Cash reserves rose to $30.8 million—an increase of $4.1 million from the prior quarter.

Key business highlights include:

• Appointment of Brandon Poe as Chief Financial Officer
• Completion of enrollment in the pivotal BioREtain® Amnion Chorion trial for diabetic foot ulcers (data expected Q4 2025)
• Expansion of the commercial team to access new sites of care
• Growth of the intellectual property portfolio to 58 issued patents and 68 pending

The excitement continues. Insiders are snapping up shares, signaling strong confidence in the company’s near-term upside, while pivotal trials for diabetic foot ulcers and new studies on venous leg ulcers accelerate.

And with a potential uplisting to a senior stock exchange under review, BSEM stands on the brink of massive visibility and broader market recognition.

This combination of record revenues, insider conviction, robust cash reserves, and cutting-edge therapies positions BioStem Technologies as one of the rare high-growth MedTech opportunities available today.

Discover how insider buying, upcoming trial data, and a possible senior exchange uplisting could propel BSEM to new heights.